Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report sent to investors on Tuesday morning. The firm issued a hold rating on the stock.

Several other research firms have also recently weighed in on EKSO. Lake Street Capital cut their price objective on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. HC Wainwright cut their target price on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th.

Ekso Bionics Trading Down 4.0 %

NASDAQ:EKSO opened at $0.69 on Tuesday. Ekso Bionics has a fifty-two week low of $0.67 and a fifty-two week high of $3.13. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The stock has a market capitalization of $15.20 million, a PE ratio of -1.07 and a beta of 1.47. The business’s 50-day simple moving average is $1.00 and its 200-day simple moving average is $1.10.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The business had revenue of $4.13 million for the quarter, compared to the consensus estimate of $6.00 million. During the same quarter last year, the firm earned ($0.24) EPS. Sell-side analysts expect that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC raised its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the period. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 as of its most recent filing with the SEC. Institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.